UT Health Science Center San Antonio doctor plays key role in FDA expediting hep C drugs
(University of Texas Health Science Center at San Antonio) The US Food and Drug Administration has granted amended Breakthrough Therapy Designation for a promising drug combination to treat the sickest hepatitis C patients -- those with advanced cirrhosis or who have had a liver transplant but the virus returned. The designation expedites drug development based on early results of the ALLY-1 clinical trial presented by Fred Poordad, M.D., from The University of Texas Health Science Center at San Antonio, at The International Liver CongressTM.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
More News: Cancer | Cancer & Oncology | Cirrhosis | Clinical Trials | Food and Drug Administration (FDA) | Health | Hepatitis | Hepatitis C | Liver | Liver Transplant | Politics | Science | Texas University | Transplant Surgery | Transplants | Urology & Nephrology